Clinical Trial Search

Primary: Number of Participants With Gastric Ulcer and/or Duodenal Ulcer — 15; 46 participants — p=<0.0001

Primary: Absence of Gastric and/or Duodenal Ulcer Throughout the Treatment Period — 167; 112 Participants

Primary: Number of Participants With Gastric Ulcers — 7; 5; 7; 4 Participants

Primary: Number of Participants With Gastric Ulcer Confirmed by Endoscopy — 9; 50 Participants — p=0.001

Primary: Number of Participants With Gastric Ulcer Confirmed by Endoscopy — 15; 51 Participants — p=0.001

Primary: The Percentage of Subjects Whose Gastric Ulcer(s) (GUs) Was (Were) Healed at Week 4 After Treatment With Esomeprazole 20 mg qd and Ranitidine 150 mg Bid in Patients…

Primary: Percentage of Participants With Clinically Significant Upper and/or Lower Gastrointestinal Events (CSULGIEs) — 1.3; 2.4 Percentage of participants — p=0.0003

Primary: Number of Participants Without Gastric and/or Duodenal Ulcer Throughout the Treatment Period — 125 Participants

Primary: Incidence of Gastroduodenal Ulcers — 28; 34 participants

Primary: Number of Subjects With Clinically Significant Upper and/or Lower Gastrointestinal Events (CSULGIEs) — 20; 81 participants — p=<0.0001

Primary: Number of Participants Who Develop Endoscopically-diagnosed Gastric Ulcers — 55; 52 participants — p=<0.0001

Primary: Incidence of Subjects With Gastroduodenal Erosions and Ulcers. — 72; 54; 19; 36 participants

Primary: Time From Randomization to Occurrence of Gastric and/or Duodenal Ulcers up to Data Cut-off Date for Interim Analysis. — 1; 16; 1; 4 Participants — p=<0.001

Primary: Frequency of Adverse Drug Reactions — 1; 1; 1; 1 participants

Primary: Endoscopic Score - Cryer Score — 4; 4 Cryer score

Primary: Gastromucosal Damage (GMD) Score of Paracetamol Tablet vs Ibuprofen Capsule — 0.33; 1.48 Scores on a scale — p=<0.0001

Primary: Degree of GI Injury at Day 15 — 23; 20; 11; 13 participants

Primary: Number of Participants With Gastric Ulcer Confirmed by Endoscopy — 7; 22 participants — p=0.005

Primary: Incidence of Gastroduodenal Ulcers — 1.4; 27.6; 2.7 Percent — p=<0.0001

Primary: Percentage of Participants Who Had One or More Adverse Drug Reactions — 0.71 Percentage of Participants

Primary: Number of Participants in Whom Peptic Ulcer Was Healed — 66; 66 participants

Primary: Number of Participants With Gastric Ulcer Confirmed by Endoscopy(EC) Aspirin 325 mg — 10; 23 participants — p=0.020

Primary: Number of Subjects Who Develop Endoscopically-diagnosed Upper Gastrointestinal Ulcers Confirmed by Endoscopy. — 40; 38 participants — p=0.0018

Primary: ITT Analysis - Percent of Patients Reporting Medication Optimization — 30; 2; 29; 65 Participants — p=<0.001

Primary: Inhibition of Serum Thromboxane B2 (TXB2) on Day 16 at 24 Hour Post IR ASA 81 mg Administration — 93.09; 87.71; 92.87; 98.72 percentage

Primary: Reduction in Pancreatitis Rate — 16.1; 4.9 percentage of participants with PEP

Primary: Percentage of Participants With Treatment Emergent Adverse Events (AEs) — 77.1; 83.8 Percentage of participants

Primary: Acute Kidney Injury — 16; 22 Participants

Primary: The Percent of Patients With Clinically Significant Upper-GI Bleeding During the Treatment Evaluation Phase — 2.7; 4.6 % of participants — p=0.393

Primary: Percentage of Participants With Satisfactory Relief of Non-ulcer Dyspepsia Symptoms — 71; 34; 82; 56 percentage of participants